TargetMol

Pemetrexed disodium

Product Code:
 
TAR-T0189L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0189L-1mL1 mL * 10 mM (in DMSO)£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0189L-50mg50mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0189L-100mg100mg£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0189L-200mg200mg£144.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Pemetrexed is a parenterally administered folate antagonist and antineoplastic agent, used in the treatment of non-small cell lung cancer and malignant mesothelioma. Pemetrexed therapy has been associated with moderate rates of serum enzyme elevations during therapy, but has not been convincingly linked to instances of acute, clinically apparent liver injury.
CAS:
150399-23-8
Formula:
C20H19N5Na2O6
Molecular Weight:
471.381
Pathway:
Metabolism; Autophagy; DNA Damage/DNA Repair; Cell Cycle/Checkpoint; Apoptosis
Purity:
0.9992
SMILES:
[Na+].[Na+].Nc1nc2[nH]cc(CCc3ccc(cc3)C(=O)NC(CCC([O-])=O)C([O-])=O)c2c(=O)[nH]1
Target:
Apoptosis; DHFR; DNA/RNA Synthesis; Antifolate; Autophagy

Documents

References

1. Shih C, et al. Cancer Res. 1997, 57(6), 1116-1123. 2. Iwahori K, et al. Int J Cancer. 2012, doi: 10.1002/ijc.27611. 3. Teicher BA, et al. Clin Cancer Res. 2000, 6(3), 12016-1023.